VALSTAR PRESERVATIVE FREE
LOE Approachingvalrubicin
NDAINTRAVESICALSOLUTIONPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALSTAR PRESERVATIVE FREE is an intravesical solution formulation of valrubicin, a chemotherapy agent administered directly into the bladder. It is indicated for the treatment of bladder cancer, specifically non-muscle invasive urothelial cancer. The preservative-free formulation represents an optimization of the original VALSTAR product for improved tolerability.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting the commercial team is transitioning from growth to defensive positioning and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALSTAR PRESERVATIVE FREE currently shows zero linked job openings, reflecting a mature, niche oncology product with limited hiring activity. Working on this product offers experience in specialty pharma and bladder cancer market dynamics, but career mobility may be constrained by the product's LOE approach and narrow indication.
Brand ManagerCommercial Operations
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.